Menu Login / Registration Search


Chemiluminescence kit for the detection of interleukin-6 in human serum.

Coming soon
Catalog Number: CL-IL6100
Size: 100 tests
Clinical topic: Sepsis & Inflammation
Diagnostic panel: COVID-19
SIRS, Sepsis, and Severe Viral Infection
  • Aid to identify the development of sepsis or SIRS in adult patients
  • Illness severity prediction and death prognosis in septic patients
  • Early identification of bacterial sepsis in infants
  • Evaluation of patients with suspected localized infection
  • Evaluation of patients with suspected systemic infection

Interleukin 6 (IL-6) is a cytokine that plays important roles in both innate and adaptive immunity. IL-6 is upregulated in patients with infection, sepsis, and septicemia and indicates an ongoing inflammatory response. Elevated IL-6 concentrations appear to correspond with the severity of sepsis. IL-6 upregulation is associated with more localized infections but it is also increased in numerous chronic inflammatory disorders, such as systemic lupus erythematosus, rheumatoid arthritis, and inflammatory bowel disease.
However, IL-6 is not diagnostic for any specific disease and IL-6 levels must be interpreted within the clinical context of the patient.

Measuring IL-6 may also be used in neonatology and pediatrics. Elevated levels upon admission to the hospital predict septic shock in children. In children with burns, it predicts septic shock and death. In infants at risk of late neonatal sepsis, IL-6 has is increased up to 48 hours before clinical manifestation of bacterial sepsis.

Sepsis and SIRS
In the sepsis and SIRS onset, IL-6 levels rise rapidly, they indicate illness severity and help in severity (or death) prognosis and risk stratification. Increasing IL-6 concentrations may also be used to predict the development of kidney injury in septic patients. In surgery patients, high levels of IL-6 predict the later development of severe sepsis.

Cytokine storm and COVID-19
Cytokine storm is a life-threatening systemic inflammatory syndrome involving elevated levels of circulating cytokines and immune-cell hyperactivation that can be triggered by infections, such as severe COVID-19 disease. IL-6 is a highly sensitive and early indicator of ongoing immunity reaction of the organism and may aid to quickly identify the development of cytokine storm in COVID-19 patients.

Technical specifications

Technical data
Related Products

Technical data

Assay time22 min
Assay stability30 days on board stability / In use stability until the expiration date at storage temperature 2-8 °C
Sample matrix Serum
Sample volume54 µL
Measuring range5–1000 ng/l
Assay/kit contentReagent Cartridge with specific reagents for the assay, magnetic particles, calibrators
Complementary productsWash buffer, Anchor® Tips, Stackable cuvettes, Trigger solutions

Undiluted samples, optional dilution 10-times


References to CLIA IL-6

  • Sakamoto T, Mabuchi A, Kuriya S, Sudo T, Aida T, Asano G, Shoji T, Yokomuro K. Production of granulocyte-macrophage colony-stimulating factor by adult murine parenchymal liver cells (hepatocytes). Reg Immunol. 1990-1991;3(5):260-7. PMID: 2129610.
    See more on PubMed
  • Tsalik EL, Jaggers LB, Glickman SW, Langley RJ, van Velkinburgh JC, Park LP, Fowler VG, Cairns CB, Kingsmore SF, Woods CW. Discriminative value of inflammatory biomarkers for suspected sepsis. J Emerg Med. 2012 Jul;43(1):97-106. doi: 10.1016/j.jemermed.2011.05.072. Epub 2011 Nov 6. PMID: 22056545; PMCID: PMC3740117.
    See more on PubMed
  • Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther. 2006;8 Suppl 2(Suppl 2):S3. doi: 10.1186/ar1917. Epub 2006 Jul 28. PMID: 16899107; PMCID: PMC3226076.
    See more on PubMed
  • Woiciechowsky C, Schöning B, Cobanov J, Lanksch WR, Volk HD, Döcke WD. Early IL-6 plasma concentrations correlate with severity of brain injury and pneumonia in brain-injured patients. J Trauma. 2002 Feb;52(2):339-45. doi: 10.1097/00005373-200202000-00021. PMID: 11834998.
    See more on PubMed
  • Kinasewitz GT, Yan SB, Basson B, Comp P, Russell JA, Cariou A, Um SL, Utterback B, Laterre PF, Dhainaut JF; PROWESS Sepsis Study Group. Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]. Crit Care. 2004 Apr;8(2):R82-90. doi: 10.1186/cc2459. Epub 2004 Feb 10. PMID: 15025782; PMCID: PMC420030.
    See more on PubMed
  • Mokart D, Merlin M, Sannini A, Brun JP, Delpero JR, Houvenaeghel G, Moutardier V, Blache JL. Procalcitonin, interleukin 6 and systemic inflammatory response syndrome (SIRS): early markers of postoperative sepsis after major surgery. Br J Anaesth. 2005 Jun;94(6):767-73. doi: 10.1093/bja/aei143. Epub 2005 Apr 22. PMID: 15849208.
    See more on PubMed
  • Küster H, Weiss M, Willeitner AE, Detlefsen S, Jeremias I, Zbojan J, Geiger R, Lipowsky G, Simbruner G. Interleukin-1 receptor antagonist and interleukin-6 for early diagnosis of neonatal sepsis 2 days before clinical manifestation. Lancet. 1998 Oct 17;352(9136):1271-7. doi: 10.1016/S0140-6736(98)08148-3. PMID: 9788457.
    See more on PubMed
  • Fioretto JR, Martin JG, Kurokawa CS, Carpi MF, Bonatto RC, Ricchetti SM, de Moraes MA, Padovani CR. Interleukin-6 and procalcitonin in children with sepsis and septic shock. Cytokine. 2008 Aug;43(2):160-4. doi: 10.1016/j.cyto.2008.05.005. Epub 2008 Jun 18. PMID: 18565757.
    See more on PubMed
  • Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med. 2020 Dec 3;383(23):2255-2273. doi: 10.1056/NEJMra2026131. PMID: 33264547; PMCID: PMC7727315.
    See more on PubMed


Safety information

Declaration of conformity

Do you want to learn more about products? We're here for you.

Please fill in
all fields
marked *